{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:05:49Z","timestamp":1776747949303,"version":"3.51.2"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Science and Technology Development Fund of Nanjing Medical University","award":["20220213"],"award-info":[{"award-number":["20220213"]}]},{"name":"The Science and Technology Development Fund of Nanjing Medical University","award":["20220206"],"award-info":[{"award-number":["20220206"]}]},{"name":"Project from Huai\u2019an Science and Technology Bureau","award":["HAB2024006"],"award-info":[{"award-number":["HAB2024006"]}]},{"name":"Project from Northern Jiangsu Institute of Clinical Medicine","award":["HAKY202400207"],"award-info":[{"award-number":["HAKY202400207"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-025-01941-w","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:39Z","timestamp":1761895899000},"page":"1253-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histone Deacetylase Inhibitor Panobinostat Augments the Antitumor Efficacy of Bromodomain Inhibitor JQ1 by Hijacking Mechanisms of Apoptosis in Head Neck Squamous Cell Carcinoma"],"prefix":"10.1007","volume":"84","author":[{"given":"Xingyu","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wubi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cairong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"1941_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4065\/83.4.489","volume":"83","author":"S Marur","year":"2008","unstructured":"Marur, S., & Forastiere, A. A. (2008). Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clinic Proceedings, 83, 489\u2013501.","journal-title":"Mayo Clinic Proceedings"},{"key":"1941_CR2","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A., Bray, F., Siegel, R. L., et al. (2015). Global cancer statistics, 2012. C Ca: A Cancer Journal for Clinicians, 65, 87\u2013108.","journal-title":"C Ca: A Cancer Journal for Clinicians"},{"key":"1941_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41571-019-0227-z","volume":"16","author":"JD Cramer","year":"2019","unstructured":"Cramer, J. D., Burtness, B., Le, Q. T., et al. (2019). The changing therapeutic landscape of head and neck cancer. Nature Reviews. Clinical Oncology, 16, 669\u2013683.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"1941_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1200\/JCO.2006.07.1464","volume":"24","author":"AA Forastiere","year":"2006","unstructured":"Forastiere, A. A., Trotti, A., Pfister, D. G., et al. (2006). Head and neck cancer: Recent advances and new standards of care. Journal of Clinical Oncology, 24, 2603\u20132605.","journal-title":"Journal of Clinical Oncology"},{"key":"1941_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4103\/jomfp.JOMFP_150_17","volume":"21","author":"KN Hema","year":"2017","unstructured":"Hema, K. N., Smitha, T., Sheethal, H. S., et al. (2017). Epigenetics in oral squamous cell carcinoma. J Oral Maxillofac Pathol, 21, 252\u2013259.","journal-title":"J Oral Maxillofac Pathol"},{"key":"1941_CR6","first-page":"27","volume":"31","author":"S Sharma","year":"2010","unstructured":"Sharma, S., Kelly, T. K., & Jones, P. A. (2010). Epigenetics in Cancer Carcinogenesis, 31 27\u201336.","journal-title":"Epigenetics in Cancer Carcinogenesis"},{"key":"1941_CR7","doi-asserted-by":"publisher","first-page":"8906","DOI":"10.18632\/oncotarget.2417","volume":"5","author":"D Martin","year":"2014","unstructured":"Martin, D., Abba, M. C., Molinolo, A. A., et al. (2014). The head and neck cancer cell oncogenome: A platform for the development of precision molecular therapies. Oncotarget, 5, 8906\u20138923.","journal-title":"Oncotarget"},{"key":"1941_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4161\/epi.7.2.18764","volume":"7","author":"EA Mazzio","year":"2012","unstructured":"Mazzio, E. A., & Soliman, K. F. (2012). Basic concepts of epigenetics: Impact of environmental signals on gene expression. Epigenetics, 7, 119\u2013130.","journal-title":"Epigenetics"},{"key":"1941_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","volume":"19","author":"Z Yang","year":"2005","unstructured":"Yang, Z., Yik, J. H., Chen, R., et al. (2005). Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Molecular Cell, 19, 535\u2013545.","journal-title":"Molecular Cell"},{"key":"1941_CR10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1126\/science.aao2793","volume":"360","author":"M Muhar","year":"2018","unstructured":"Muhar, M., Ebert, A., Neumann, T., et al. (2018). SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. Science, 360, 800\u2013805.","journal-title":"Science"},{"key":"1941_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cellimm.2019.02.001","volume":"337","author":"ME White","year":"2019","unstructured":"White, M. E., Fenger, J. M., & Carson3, W. E. (2019). Emerging roles of and therapeutic strategies targeting BRD4 in cancer. Cellular Immunology, 337, 48\u201353.","journal-title":"Cellular Immunology"},{"key":"1941_CR12","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-13-0122-T","volume":"73","author":"MF Segura","year":"2013","unstructured":"Segura, M. F., Fontanals-Cirera, B., Gaziel-Sovran, A., et al. (2013). BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Research, 73, 6264\u20136276.","journal-title":"Cancer Research"},{"key":"1941_CR13","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.7150\/thno.31581","volume":"9","author":"Y Wu","year":"2019","unstructured":"Wu, Y., Wang, Y., Diao, P., et al. (2019). Therapeutic targeting of BRD4 in head neck squamous cell carcinoma. Theranostics, 9, 1777\u20131793.","journal-title":"Theranostics"},{"key":"1941_CR14","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz, J. A., Conery, A. R., Bryant, B. M., et al. (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A, 108, 16669\u201316674.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1941_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani, I. A., Dommeti, V. L., Wang, X., et al. (2014). Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature, 510, 278\u2013282.","journal-title":"Nature"},{"key":"1941_CR16","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-0459","volume":"78","author":"B Leonard","year":"2018","unstructured":"Leonard, B., Brand, T. M., O\u2019Keefe, R. A., et al. (2018). BET Inhibition overcomes receptor tyrosine Kinase-Mediated cetuximab resistance in HNSCC. Cancer Research, 78, 4331\u20134343.","journal-title":"Cancer Research"},{"key":"1941_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.canlet.2019.11.027","volume":"469","author":"W Zhang","year":"2020","unstructured":"Zhang, W., Ge, H., Jiang, Y., et al. (2020). Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma. Cancer Letters, 469, 510\u2013523.","journal-title":"Cancer Letters"},{"key":"1941_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","volume":"8","author":"A Stathis","year":"2018","unstructured":"Stathis, A., & Bertoni, F. (2018). BET proteins as targets for anticancer treatment. Cancer Discovery, 8, 24\u201336.","journal-title":"Cancer Discovery"},{"key":"1941_CR19","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","volume":"3","author":"C Berthon","year":"2016","unstructured":"Berthon, C., Raffoux, E., Thomas, X., et al. (2016). Bromodomain inhibitor OTX015 in patients with acute leukaemia: A dose-escalation, phase 1 study. Lancet Haematol, 3, e186\u2013195.","journal-title":"Lancet Haematol"},{"key":"1941_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu, S., Lin, C. Y., He, H. H., et al. (2016). Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature, 529, 413\u2013417.","journal-title":"Nature"},{"key":"1941_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.3952","volume":"21","author":"PK Mazur","year":"2015","unstructured":"Mazur, P. K., Herner, A., Mello, S. S., et al. (2015). Combined Inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 21, 1163\u20131171.","journal-title":"Nature Medicine"},{"key":"1941_CR22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","volume":"23","author":"P Zhang","year":"2017","unstructured":"Zhang, P., Wang, D., Zhao, Y., et al. (2017). Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nature Medicine, 23, 1055\u20131062.","journal-title":"Nature Medicine"},{"key":"1941_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert, P., Roth, M., Neumann, T., et al. (2015). Transcriptional plasticity promotes primary and acquired resistance to BET Inhibition. Nature, 525, 543\u2013547.","journal-title":"Nature"},{"key":"1941_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong, C. Y., Gilan, O., Lam, E. Y., et al. (2015). BET inhibitor resistance emerges from leukaemia stem cells. Nature, 525, 538\u2013542.","journal-title":"Nature"},{"key":"1941_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","volume":"6","author":"A Stathis","year":"2016","unstructured":"Stathis, A., Zucca, E., Bekradda, M., et al. (2016). Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015\/MK-8628. Cancer Discovery, 6, 492\u2013500.","journal-title":"Cancer Discovery"},{"key":"1941_CR26","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin, J., Soria, J. C., Stathis, A., et al. (2018). Phase Ib trial with Birabresib, a Small-Molecule inhibitor of bromodomain and extraterminal Proteins, in patients with selected advanced solid tumors. Journal of Clinical Oncology, 36, 3007\u20133014.","journal-title":"Journal of Clinical Oncology"},{"key":"1941_CR27","doi-asserted-by":"publisher","first-page":"eaal1645","DOI":"10.1126\/scitranslmed.aal1645","volume":"26","author":"L. Yang","year":"2017","unstructured":"Yang, L., Zhang, Y., Shan, W. (2017). Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP Inhibition. Science Translational Medicine, 26, eaal1645.","journal-title":"Science Translational Medicine"},{"key":"1941_CR28","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1038\/s41388-018-0135-1","volume":"37","author":"S Bolin","year":"2018","unstructured":"Bolin, S., Borgenvik, A., Persson, C. U., et al. (2018). Combined BET bromodomain and CDK2 Inhibition in MYC-driven Medulloblastoma. Oncogene, 37, 2850\u20132862.","journal-title":"Oncogene"},{"key":"1941_CR29","doi-asserted-by":"publisher","first-page":"700947","DOI":"10.3389\/fonc.2021.700947","volume":"11","author":"R Hai","year":"2021","unstructured":"Hai, R., He, L., Shu, G., et al. (2021). Characterization of histone deacetylase mechanisms in cancer development. Frontiers in Oncology, 11, 700947.","journal-title":"Frontiers in Oncology"},{"key":"1941_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12967-024-05169-9","volume":"22","author":"M Xu","year":"2024","unstructured":"Xu, M., Hou, Y., Li, N., et al. (2024). Targeting histone deacetylases in head and neck squamous cell carcinoma: Molecular mechanisms and therapeutic targets. J Transl Med, 22, 418.","journal-title":"J Transl Med"},{"key":"1941_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/or.2021.7997","volume":"45","author":"A. Kakiuchi","year":"2021","unstructured":"Kakiuchi, A., Kakuki, T., Ohwada, K. (2021). HDAC inhibitors suppress the proliferation, migration and invasiveness of human head and neck squamous cell carcinoma cells via p63\u2013mediated tight junction molecules and p21\u2013mediated growth arrest. Oncology Reports, 45, 46.","journal-title":"Oncology Reports"},{"key":"1941_CR32","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"3","author":"Y. Li","year":"2016","unstructured":"Li, Y., & Seto, E. (2016). HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med, 3, a026831.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1941_CR33","doi-asserted-by":"publisher","first-page":"113825","DOI":"10.1016\/j.ejmech.2021.113825","volume":"226","author":"M Zhou","year":"2021","unstructured":"Zhou, M., Yuan, M., Zhang, M., et al. (2021). Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. European Journal of Medicinal Chemistry, 226, 113825.","journal-title":"European Journal of Medicinal Chemistry"},{"key":"1941_CR34","unstructured":"Panobinostat, L. T. (2012). Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD)."},{"key":"1941_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40360-023-00686-7","volume":"24","author":"B Sheng","year":"2023","unstructured":"Sheng, B., Wang, W., Xia, D., et al. (2023). Panobinostat (LBH589) combined with AM1241 induces cervical cancer cell apoptosis through autophagy pathway. BMC Pharmacol Toxicol, 24, 45.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1941_CR36","doi-asserted-by":"publisher","first-page":"13019","DOI":"10.3390\/ijms232113019","volume":"27","author":"M. Ovejero-Sanchez","year":"2022","unstructured":"Ovejero-Sanchez, M., Asensio-Juarez, G., Gonzalez, M. (2022). Panobinostat synergistically enhances the cytotoxicity of microtubule destabilizing drugs in ovarian cancer cells. International Journal of Molecular Sciences, 27, 13019.","journal-title":"International Journal of Molecular Sciences"},{"key":"1941_CR37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41416-019-0680-6","volume":"122","author":"W Zhang","year":"2020","unstructured":"Zhang, W., Cheng, J., Diao, P., et al. (2020). Therapeutically targeting head and neck squamous cell carcinoma through synergistic Inhibition of LSD1 and JMJD3 by TCP and GSK-J1. British Journal of Cancer, 122, 528\u2013538.","journal-title":"British Journal of Cancer"},{"key":"1941_CR38","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.15252\/embr.201540945","volume":"16","author":"T Zhang","year":"2015","unstructured":"Zhang, T., Cooper, S., & Brockdorff, N. (2015). The interplay of histone modifications - writers that read. Embo Reports, 16, 1467\u20131481.","journal-title":"Embo Reports"},{"key":"1941_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mrrev.2017.09.003","volume":"780","author":"F Gong","year":"2019","unstructured":"Gong, F., & Miller, K. M. (2019). Histone methylation and the DNA damage response. Mutat Res Rev Mutat Res, 780, 37\u201347.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"1941_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-018-0916-y","volume":"37","author":"W Meng","year":"2018","unstructured":"Meng, W., Wang, B., Mao, W., et al. (2018). Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma. Journal of Experimental & Clinical Cancer Research : Cr, 37, 241.","journal-title":"Journal of Experimental & Clinical Cancer Research : Cr"},{"key":"1941_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-022-02530-y","volume":"41","author":"MJ Kling","year":"2022","unstructured":"Kling, M. J., Kesherwani, V., Mishra, N. K., et al. (2022). A novel dual epigenetic approach targeting BET proteins and HDACs in group 3 (MYC-driven) Medulloblastoma. Journal of Experimental & Clinical Cancer Research : Cr, 41, 321.","journal-title":"Journal of Experimental & Clinical Cancer Research : Cr"},{"key":"1941_CR42","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1158\/1078-0432.CCR-15-1666","volume":"22","author":"J Shahbazi","year":"2016","unstructured":"Shahbazi, J., Liu, P. Y., Atmadibrata, B., et al. (2016). The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor Panobinostat synergistically reduce N-Myc expression and induce anticancer effects. Clinical Cancer Research, 22, 2534\u20132544.","journal-title":"Clinical Cancer Research"},{"key":"1941_CR43","doi-asserted-by":"publisher","first-page":"603","DOI":"10.18632\/aging.100934","volume":"8","author":"G Pistritto","year":"2016","unstructured":"Pistritto, G., Trisciuoglio, D., Ceci, C., et al. (2016). Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY), 8, 603\u2013619.","journal-title":"Aging (Albany NY)"},{"key":"1941_CR44","doi-asserted-by":"publisher","first-page":"146461","DOI":"10.1016\/j.gene.2022.146461","volume":"827","author":"L Zhao","year":"2022","unstructured":"Zhao, L., Liang, J., Zhong, W., et al. (2022). Expression and prognostic analysis of BGN in head and neck squamous cell carcinoma. Gene, 827, 146461.","journal-title":"Gene"},{"key":"1941_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jop.13381","volume":"52","author":"M Liu","year":"2023","unstructured":"Liu, M., Wang, W., Piao, S., et al. (2023). Relationship of Biglycan and decorin expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 52, 20\u201328.","journal-title":"Journal of Oral Pathology and Medicine"},{"key":"1941_CR46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/ijms22010240","volume":"29","author":"N. Kitamura","year":"2020","unstructured":"Kitamura, N., Sento, S., Yoshizawa, Y. (2020). Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma. International Journal of Molecular Sciences, 29, 240.","journal-title":"International Journal of Molecular Sciences"},{"key":"1941_CR47","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology, 740, 364\u2013378.","journal-title":"European Journal of Pharmacology"},{"key":"1941_CR48","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang, C., Xu, C., Gao, X., et al. (2022). Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics, 12, 2115\u20132132.","journal-title":"Theranostics"},{"key":"1941_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10528-019-09941-1","volume":"58","author":"J Gazdzicka","year":"2020","unstructured":"Gazdzicka, J., Golabek, K., Strzelczyk, J. K., et al. (2020). Epigenetic modifications in head and neck cancer. Biochemical Genetics, 58, 213\u2013244.","journal-title":"Biochemical Genetics"},{"key":"1941_CR50","first-page":"e11725","volume":"12","author":"C Hillyar","year":"2020","unstructured":"Hillyar, C., Rallis, K. S., & Varghese, J. (2020). Advances in Epigenetic Cancer Therapeutics Cureus, 12 e11725.","journal-title":"Advances in Epigenetic Cancer Therapeutics Cureus"},{"key":"1941_CR51","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/0022034518816947","volume":"98","author":"MV Bais","year":"2019","unstructured":"Bais, M. V. (2019). Impact of epigenetic regulation on head and neck squamous cell carcinoma. Journal of Dental Research, 98, 268\u2013276.","journal-title":"Journal of Dental Research"},{"key":"1941_CR52","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.3390\/cancers13205241","volume":"13","author":"K. Burkitt","year":"2021","unstructured":"Burkitt, K., & Saloura, V. (2021). Epigenetic modifiers as novel therapeutic targets and a systematic review of clinical studies investigating epigenetic inhibitors in head and neck cancer. Cancers (Basel), 13, 5241.","journal-title":"Cancers (Basel)"},{"key":"1941_CR53","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","volume":"17","author":"B Donati","year":"2018","unstructured":"Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018). BRD4 and cancer: Going beyond transcriptional regulation. Molecular Cancer, 17, 164.","journal-title":"Molecular Cancer"},{"key":"1941_CR54","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P., Qi, J., Picaud, S., et al. (2010). Selective Inhibition of BET bromodomains. Nature, 468, 1067\u20131073.","journal-title":"Nature"},{"key":"1941_CR55","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1172\/JCI126327","volume":"130","author":"L Wang","year":"2020","unstructured":"Wang, L., Xu, M., Kao, C. Y., et al. (2020). Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. J Clin Invest, 130, 1782\u20131792.","journal-title":"J Clin Invest"},{"key":"1941_CR56","doi-asserted-by":"publisher","first-page":"108354","DOI":"10.1016\/j.pharmthera.2023.108354","volume":"243","author":"J Guo","year":"2023","unstructured":"Guo, J., Zheng, Q., & Peng, Y. (2023). BET proteins: Biological functions and therapeutic interventions. Pharmacology & Therapeutics, 243, 108354.","journal-title":"Pharmacology & Therapeutics"},{"key":"1941_CR57","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","volume":"64","author":"P Tang","year":"2021","unstructured":"Tang, P., Zhang, J., Liu, J., et al. (2021). Targeting bromodomain and extraterminal proteins for drug discovery: From current progress to technological development. Journal of Medicinal Chemistry, 64, 2419\u20132435.","journal-title":"Journal of Medicinal Chemistry"},{"key":"1941_CR58","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","volume":"34","author":"AB Iniguez","year":"2018","unstructured":"Iniguez, A. B., Alexe, G., Wang, E. J., et al. (2018). Resistance to Epigenetic-Targeted therapy engenders tumor cell vulnerabilities associated with enhancer remodeling. Cancer Cell, 34, 922\u2013938e927.","journal-title":"Cancer Cell"},{"key":"1941_CR59","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.3390\/cancers14184474","volume":"14","author":"A. Juan","year":"2022","unstructured":"Juan, A., Noblejas-Lopez, M. D. M., Bravo, I. (2022). Enhanced antitumoral activity of encapsulated BET inhibitors when combined with PARP inhibitors for the treatment of Triple-Negative breast and ovarian cancers, Cancers, 14, 4474.","journal-title":"Cancers"},{"key":"1941_CR60","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","volume":"13","author":"W Fiskus","year":"2014","unstructured":"Fiskus, W., Sharma, S., Qi, J., et al. (2014). Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Molecular Cancer Therapeutics, 13, 1142\u20131154.","journal-title":"Molecular Cancer Therapeutics"},{"key":"1941_CR61","doi-asserted-by":"publisher","first-page":"119504","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021). Epigenetic modulation and Understanding of HDAC inhibitors in cancer therapy. Life Sciences, 277, 119504.","journal-title":"Life Sciences"},{"key":"1941_CR62","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.2174\/13816128113199990527","volume":"20","author":"S Xu","year":"2014","unstructured":"Xu, S., Ren, J., Chen, H. B., et al. (2014). Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells. Curr Pharm Des, 20, 1881\u20131887.","journal-title":"Curr Pharm Des"},{"key":"1941_CR63","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.2147\/CMAR.S254412","volume":"12","author":"S Huan","year":"2020","unstructured":"Huan, S., Gui, T., Xu, Q., et al. (2020). Combination BET family protein and HDAC Inhibition synergistically elicits chondrosarcoma cell apoptosis through RAD51-Related DNA damage repair. Cancer Manag Res, 12, 4429\u20134439.","journal-title":"Cancer Manag Res"},{"key":"1941_CR64","doi-asserted-by":"crossref","unstructured":"He, J., Ouyang, S., Zhao, Y., et al. (2023). Prognostic value of CAV1 and CAV2 in head and neck squamous cell carcinoma (p. 13). Biomolecules.","DOI":"10.3390\/biom13020303"},{"key":"1941_CR65","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.3892\/mmr.2015.4383","volume":"12","author":"X Xing","year":"2015","unstructured":"Xing, X., Gu, X., & Ma, T. (2015). Knockdown of Biglycan expression by RNA interference inhibits the proliferation and invasion of, and induces apoptosis in, the HCT116 colon cancer cell line. Molecular Medicine Reports, 12, 7538\u20137544.","journal-title":"Molecular Medicine Reports"},{"key":"1941_CR66","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.canlet.2019.11.027","volume":"469","author":"Wei Zhang","year":"2020","unstructured":"Wei, Zhang Han, Ge Yue, Jiang Rong, Huang Yaping, Wu Dongmiao, Wang Songsong, Guo Sheng, Li Yanling, Wang Hongbing, Jiang Jie, Cheng (2020) Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma. Cancer Letters, 469, 510-523 https:\/\/doi.org\/10.1016\/j.canlet.2019.11.027","journal-title":"Cancer Letters"},{"issue":"4","key":"1941_CR67","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41416-019-0680-6","volume":"122","author":"Zhang Jie Wei","year":"2020","unstructured":"Wei, Zhang Jie, Cheng Pengfei, Diao Dongmiao, Wang Wei, Zhang Hongbing, Jiang Yanling, Wang (2020) Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1. Abstract British Journal of Cancer 122(4) 528-538. https:\/\/doi.org\/10.1038\/s41416-019-0680-6","journal-title":"Abstract British Journal of Cancer"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-025-01941-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-025-01941-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-025-01941-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:02:09Z","timestamp":1772863329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-025-01941-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1941"],"URL":"https:\/\/doi.org\/10.1007\/s12013-025-01941-w","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"26 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with ARRIVE guidelines and approved by Institutional Animal Care and Use Committee of the Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University (YX-Z-2024-031-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"No parts of this manuscript are being considered for publication elsewhere. All authors have read and finally approved this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}